Wegovy — higher-dose semaglutide specifically FDA-approved for obesity treatment — received cardiovascular mortality reduction approval in 2024, transforming it from a lifestyle drug to a medical necessity for covered insurance reimbursement. The expanded indication drove prescribing growth across cardiac care and primary care physicians.
Wegovy currently drives about 1.2M/mo in monthly search volume, +623% year over year. Common use cases include Weight loss program marketing, Healthcare market research, Obesity treatment content.
Related keywords people also research: Ozempic, GLP 1 Medications, Semaglutide, Berberine, GLP 1 Diet Protocol, tirzepatide.
Explore more Healthcare Trends.
More healthcare trends: GLP-1 Medications, Ozempic, Semaglutide, Concierge Medicine, Preventive Bloodwork, Functional Medicine, Telehealth, Longevity Medicine, Biomarker Testing, Wearable Health Monitoring, Postpartum Care, Pelvic Floor Therapy.
Tagged: Wegovy, Weight loss, FDA-approved.